drugset
drugset / Trial / NCT01253655

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

NCT01253655 ↗

Phase 1 Completed 6 enrolled Pfizer Yale University · collab
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the relationship between plasma drug levels and receptor binding in brain using PET; and to evaluate safety and tolerability after a single administration of PF-05212365 in healthy volunteers

Timeline

Start
2010-11
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CERLAPIRDINE Small molecule 1 mg Oral
Subject CERLAPIRDINE Small molecule 3 mg Oral
Subject CERLAPIRDINE Small molecule 5 mg Oral

Indications

No indication recorded.